Amgen (AMGN) Stock Gains in After-Hours Trading on Earnings Beat
Neupogen revenues decreased 5% to $284 million. It attributed gains to increases in non-advertising revenue from subscriber fees, content licensing and spectrum leasing. Among other key drugs, sales of osteoporosis drugs, Prolia and Xgeva, grew 25% and 19% YoY, respectively.
Posted On Oct 29 2015